Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Viral Hepatitis

Quick Links

Veterans Crisis Line Badge
My healthevet badge

Drug Interactions between HCV DAAs and HIV Antiretrovirals

for Health Care Providers

Drug Interactions between Hepatitis C Direct-Acting Antivirals and HIV Antiretrovirals

The table below indicates the clinically significant published drug interactions between hepatitis C direct-acting antivirals (DAA) and HIV antiretrovirals.

Drug Interactions between HCV DAAs and HIV Antiretrovirals
DAAMechanismFDA statusGenotypeBarrier to resistancePotential ARV interactions

Sources:

TelaprevirNS3/4A protease inhibitorApproved 20111Low

Contraindicated with protease inhibitors and NNRTIs except atazanavir/ritonavir and efavirenz

Requires increased dosage of telaprevir (1125mg Q8h) when administered with efavirenz

BoceprevirNS3/4A protease inhibitorApproved 20111Low

Contraindicated with boosted and unboosted protease inhibitors and efavirenz

No clinically significant interactions with raltegravir

SimeprevirNS3/4A protease inhibitorApproved 20131, 2, 4, 5, 6Low

Concentrations decreased in presence of efavirenz

Concentrations increased in presence of darunavir/ritonavir, ritonavir (100mg bid) and cobicistat-containing products. It is not recommended to co-administer simeprevir with any HIV protease inhibitor (with or without ritonavir).

No clinically significant interactions with raltegravir, rilpivirine, tenofovir.

SofosbuvirNS5B RNA polymerase inhibitorApproved 20131-6High

Concentrations decreased in presence of tipranavir/ritonavir; coadministration not recommended.

No clinically significant interactions with darunavir/ritonavir, efavirenz, emtricitabine, raltegravir, rilpivirine, or tenofovir.